Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations
about
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentConcomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugsAssociation between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studiesProton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trialReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Cardioprotective aspirin users and their excess risk of upper gastrointestinal complicationsRisk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsExcess long-term mortality following non-variceal upper gastrointestinal bleeding: a population-based cohort studyA prospective study of aspirin use and the risk of gastrointestinal bleeding in menConsiderations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) studyAspirin for primary cardiovascular prevention: when is it worth the risks?British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesMeasuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics.The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.OTC analgesics and drug interactions: clinical implications.The Effect of Antiplatelet Drugs on the Patency Rate of Arterio-venous Fistulae in Hemodialysis Patients.Gastroprotective [6]-Gingerol Aspirinate as a Novel Chemopreventive Prodrug of Aspirin for Colon Cancer.Clinical pharmacology of antithrombotic drugs in coronary artery disease.Predictive factors for intractability to endoscopic hemostasis in the treatment of bleeding gastroduodenal peptic ulcers in Japanese patients.Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.The NSAID dilemma: managing osteoarthritis in high-risk patients.Identifying determinants of variability to tailor aspirin therapy.Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?Use of antiplatelet agents in patients with atherosclerotic disease.Defining a reference set to support methodological research in drug safety.Aspirin for cardioprotection and strategies to improve patient adherence.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms.Roles of NSAIDs and aspirin in bleeding peptic ulcers : NSAIDs, aspirin and peptic ulcers.
P2860
Q21195670-F03C4F4A-EC1A-4999-B4AB-599A23AD5F25Q27027977-6A33AC42-B103-42A9-86B5-0686F4B80BA1Q28168123-A4568406-F7D9-445A-8478-70600A7D8057Q28191843-00630C6B-5303-447E-AA42-75D34FE440DAQ28196664-18D907F9-6797-4C87-9AC0-22FC8491959EQ28200403-15807307-4B88-4BA4-826E-18EE090BEA93Q28200511-810DABC6-D842-4A4B-9C35-32518B8DAF74Q28217824-98C51EE5-CD5F-4397-8828-246D56F2C45CQ28706320-0C43EF21-EF44-4E8E-99EB-43475429C884Q28743884-4E080BCA-57FB-4B9C-AB85-FDBC41A7388CQ30251866-6CABE4F2-3569-4D2C-93B2-46BEAA53CA3DQ33401679-A10E102F-822A-4E2B-8CFB-3CE27405BF5EQ33774734-BE49EC92-9DFF-48FD-93A8-64965CA08D45Q34380645-D5934576-4016-4099-A737-F4B751233C0CQ35117393-9E0D7A62-B9A9-4205-A503-E3707AEDC599Q35752619-96D919C2-9F30-48CD-93EF-1EDAC250FD5EQ35799572-1342A858-A644-4E32-B3B0-B4BDFAF9ED07Q35828322-32A337C4-731D-4D2C-B58C-2E15C569CD22Q36094923-37B78C28-DD03-426F-B04A-2411A4B35882Q36192713-11DB4B9B-5D4A-44F1-AB2A-64A4946E2A12Q36481601-0652DFB0-3860-44DF-9868-A1213176AA57Q37408022-7FA91253-4DB3-459C-B243-BA7239F6CF2EQ37571099-792A6556-02BC-402D-A5AC-BE1581B7274AQ37591007-F1B5A5DF-C6B6-4AAB-946F-7CF061E55272Q37714585-6E62DB69-AD62-4897-9869-1E8F76118BC3Q37731873-57C12073-F2D0-4ACE-ACCF-5C07AA89E2E5Q37949849-168FF381-1127-48D2-8FA7-FE7200178632Q38087384-853C3FFE-8EE5-4B81-B0B9-17A11B3F4D92Q38114868-0C0EDCEA-1D07-4A8C-BC65-D79F4CE850D9Q38151446-C2FBEE6A-8CFB-4BDB-84F0-6F7C637BBDDCQ38156066-2A5E798E-23C1-4851-BCA0-10EF369161A2Q38176141-9F1C5375-8A74-41B4-A506-C33587039AE7Q38196383-9CE45CD3-1AA1-4E64-98E6-4FC969040E41Q38271121-DEBC6A00-9956-4417-B62C-2AFCC3F12AFFQ38321114-4ACA9E00-A46A-4004-8426-D8B7EDAF9A40Q38421094-5F16A2F1-1211-459C-B963-F75D3AD26DFAQ38809179-4B4BE74B-3D5B-49D5-8DDB-AA125F0D6999Q38987249-98E6CAEE-7F61-479F-B3D3-AA081D60F0DEQ39658839-0773538C-CB88-4F10-8959-CC13A5D71B20Q40086146-7B7CE920-D620-4671-A0EA-AC78BD898794
P2860
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations
description
2001 nî lūn-bûn
@nan
2001 թուականին հրատարակուած գիտական յօդուած
@hyw
2001 թվականին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@ast
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@en
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@nl
type
label
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@ast
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@en
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@nl
prefLabel
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@ast
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@en
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@nl
P2860
P3181
P356
P1476
Risk of upper gastrointestinal ...... nd enteric-coated formulations
@en
P2093
L A García Rodríguez
P2860
P2888
P3181
P356
10.1186/1472-6904-1-1
P407
P577
2001-02-13T00:00:00Z
P5875
P6179
1011440313